Abstract

BackgroundUric acid (UA) is an antioxidant found in human serum. However, high UA levels may also have pro-oxidant functions. According to previous research, aldose reductase (AR) plays a vital role in the oxidative stress-related complications of diabetes. We sought to determine the mechanism by which UA becomes deleterious at high concentrations as well as the effect of AR in this process.MethodEndothelial cells were divided into three groups cultured without UA or with 300 μM or 600 μM UA. The levels of total reactive oxygen species (ROS), of four ROS components, and of NO and NOX4 expression were measured. Changes in the above molecules were detected upon inhibiting NOX4 or AR, and serum H2O2 and vWF levels were measured in vivo.ResultsIncreased AR expression in high UA-treated endothelial cells enhanced ROS production by activating NADPH oxidase. These effects were blocked by the AR inhibitor epalrestat. 300 μM UA decreased the levels of the three major reactive oxygen species (ROS) components: O2•-, •OH, and 1O2. However, when the UA concentration was increased, both O2•- levels and downstream H2O2 production significantly increased. Finally, an AR inhibitor reduced H2O2 production in hyperuricemic mice and protected endothelial cell function.ConclusionsOur findings indicate that inhibiting AR or degrading H2O2 could protect endothelial function and maintain the antioxidant activities of UA. These findings provide new insight into the role of UA in chronic kidney disease.

Highlights

  • Uric acid (UA) is an antioxidant found in human serum

  • Increased aldose reductase (AR) expression in high UA-treated endothelial cells enhanced ROS production by activating NADPH oxidase. These effects were blocked by the AR inhibitor epalrestat. 300 μM UA decreased the levels of the three major reactive oxygen species (ROS) components: O2, Hydroxyl radical (OH), and Singlet oxygen (1O2)

  • High UA increased intracellular ROS production, AR activity and endothelial cell impairment but decreased nitric oxide (NO) release To confirm the impairment of endothelial cells by UA treatment, we evaluated the effect of different UA concentrations on ROS production and NO release in Human umbilical vein endothelial cells (HUVEC) UA (300 μM) reduced total ROS levels in endothelial cells, whereas high UA (600 μM) treatment increased intracellular ROS production (Fig. 1a)

Read more

Summary

Introduction

Uric acid (UA) is an antioxidant found in human serum. Aldose reductase (AR) plays a vital role in the oxidative stress-related complications of diabetes. We sought to determine the mechanism by which UA becomes deleterious at high concentrations as well as the effect of AR in this process. Uric acid (UA) is the final enzymatic product in the degradation of purine nucleosides and free bases in humans and the great apes [1,2,3]. How the effects of UA become deleterious at high concentrations is unknown. The pathogenesis of these diseases is extremely complex and incompletely understood, oxidative stress clearly plays a central role. UA and/ or its downstream radicals can trigger intracellular oxidant production via the ubiquitous NADPH oxidase-dependent pathway, thereby resulting in oxidative stress

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.